Table 3. Univariate and multivariate Cox analyses of OS for NSCLC and pure SCLC patients in unmatched and matched cohorts.
| Characteristics | CSCLC (n=871) and pure SCLC (n=45,433) | 1:4 match of CSCLC (n=871) and pure SCLC (n=3,366) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | ||||||||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | ||||
| Age (years) | |||||||||||||||
| ≤60 | 1 | 1 | 1 | 1 | |||||||||||
| 60–70 | 1.17 | 1.14–1.20 | <0.001 | 1.14 | 1.11–1.17 | <0.001 | 1.17 | 1.08–1.27 | <0.001 | 1.19 | 1.10–1.30 | <0.001 | |||
| >70 | 1.60 | 1.56–1.64 | <0.001 | 1.41 | 1.37–1.44 | <0.001 | 1.55 | 1.43–1.68 | <0.001 | 1.52 | 1.40–1.66 | <0.001 | |||
| Gender | |||||||||||||||
| Female | 1 | 1 | 1 | 1 | |||||||||||
| Male | 1.18 | 1.16–1.20 | <0.001 | 1.16 | 1.14–1.18 | <0.001 | 1.38 | 1.29–1.47 | <0.001 | 1.31 | 1.23–1.40 | <0.001 | |||
| Race | |||||||||||||||
| White | 1 | 1 | 1 | 1 | |||||||||||
| Black | 0.93 | 0.90–0.97 | <0.001 | 0.94 | 0.91–0.97 | <0.001 | 1.11 | 1.01–1.23 | 0.032 | 1.02 | 0.93–1.13 | 0.646 | |||
| Other | 0.96 | 0.91–1.00 | 0.061 | 0.91 | 0.87–0.95 | <0.001 | 1.00 | 0.85–1.18 | 0.985 | 0.73 | 0.62–0.86 | <0.001 | |||
| Primary site | |||||||||||||||
| Left upper lobe | 1 | 1 | 1 | 1 | |||||||||||
| Left lower lobe | 1.06 | 1.02–1.10 | 0.004 | 1.03 | 0.99–1.07 | 0.112 | 0.95 | 0.85–1.07 | 0.411 | 1.03 | 0.92–1.16 | 0.590 | |||
| Right upper lobe | 0.98 | 0.96–1.01 | 0.231 | 1.00 | 0.97–1.03 | 0.881 | 0.94 | 0.86–1.03 | 0.183 | 0.93 | 0.85–1.02 | 0.130 | |||
| Right middle lobe | 0.99 | 0.94–1.04 | 0.638 | 0.99 | 0.94–1.04 | 0.639 | 0.87 | 0.73–1.04 | 0.137 | 0.82 | 0.69–0.98 | 0.031 | |||
| Right lower lobe | 1.08 | 1.04–1.12 | <0.001 | 1.04 | 1.01–1.08 | 0.026 | 1.00 | 0.89–1.12 | 0.983 | 1.07 | 0.95–1.21 | 0.241 | |||
| Main bronchus | 1.12 | 1.08–1.16 | <0.001 | 1.05 | 1.01–1.09 | 0.006 | 1.38 | 1.21–1.57 | <0.001 | 1.11 | 0.97–1.26 | 0.144 | |||
| Unspecific | 1.32 | 1.28–1.36 | <0.001 | 1.08 | 1.05–1.11 | <0.001 | 1.63 | 1.46–1.83 | <0.001 | 1.10 | 0.98–1.23 | 0.122 | |||
| T | |||||||||||||||
| T1 | 1 | 1 | 1 | 1 | |||||||||||
| T2 | 1.31 | 1.26–1.35 | <0.001 | 1.23 | 1.19–1.27 | <0.001 | 1.62 | 1.47–1.78 | <0.001 | 1.27 | 1.15–1.40 | <0.001 | |||
| T3 | 1.47 | 1.40–1.55 | <0.001 | 1.36 | 1.29–1.43 | <0.001 | 2.15 | 1.82–2.54 | <0.001 | 1.54 | 1.29–1.83 | <0.001 | |||
| T4 | 1.70 | 1.65–1.76 | <0.001 | 1.43 | 1.39–1.48 | <0.001 | 2.64 | 2.41–2.90 | <0.001 | 1.62 | 1.46–1.79 | <0.001 | |||
| N | |||||||||||||||
| N0 | 1 | 1 | 1 | 1 | |||||||||||
| N1 | 1.10 | 1.05–1.14 | <0.001 | 1.14 | 1.09–1.19 | <0.001 | 1.33 | 1.17–1.51 | <0.001 | 1.38 | 1.22–1.57 | <0.001 | |||
| N2 | 1.39 | 1.35–1.43 | <0.001 | 1.31 | 1.27–1.35 | <0.001 | 2.07 | 1.91–2.24 | <0.001 | 1.52 | 1.39–1.66 | <0.001 | |||
| N3 | 1.47 | 1.42–1.52 | <0.001 | 1.34 | 1.29–1.38 | <0.001 | 2.20 | 1.99–2.44 | <0.001 | 1.36 | 1.22–1.53 | <0.001 | |||
| M | |||||||||||||||
| M0 | 1 | 1 | 1 | 1 | |||||||||||
| M1 | 2.13 | 2.08–2.17 | <0.001 | 1.78 | 1.74–1.82 | <0.001 | 2.94 | 2.74–3.15 | <0.001 | 2.02 | 1.88–2.18 | <0.001 | |||
| Histology | |||||||||||||||
| CSCLC | 1 | 1 | 1 | ||||||||||||
| Pure SCLC | 1.40 | 1.30–1.50 | <0.001 | 1.10 | 1.02–1.19 | 0.012 | 1.06 | 0.97–1.14 | 0.185 | ||||||
| Surgery | |||||||||||||||
| None | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 0.38 | 0.36–0.41 | <0.001 | 0.44 | 0.42–0.48 | <0.001 | 0.36 | 0.33–0.39 | <0.001 | 0.51 | 0.46–0.56 | <0.001 | |||
| Radiation | |||||||||||||||
| None | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 0.49 | 0.48–0.50 | <0.001 | 0.67 | 0.42–0.69 | <0.001 | 0.72 | 0.67–0.76 | <0.001 | 0.77 | 0.71–0.82 | <0.001 | |||
| Chemotherapy | |||||||||||||||
| None | 1 | 1 | 1 | 1 | |||||||||||
| Yes | 0.36 | 0.36–0.37 | <0.001 | 0.39 | 0.38–0.40 | <0.001 | 0.58 | 0.54–0.62 | <0.001 | 0.51 | 0.47–0.55 | <0.001 | |||
OS, overall survival; CSCLC, combined small cell lung cancer; SCLC, small cell lung cancer; HR, hazard ratio; CI, confidence interval.